J. Trevillyan

发表

Dipeptidyl peptidase IV inhibitors for type 2 diabetes and metabolic syndrome

P. Wiedeman, J. Trevillyan, 2005 .

Discovery of a potent, selective protein tyrosine phosphatase 1B inhibitor using a linked-fragment strategy.

Gang Liu, P. Hajduk, S. Fesik, 2003, Journal of the American Chemical Society.

Human T lymphocytes express a protein-tyrosine kinase homologous to p56LSTRA.

Y. Lin, J. Trevillyan, S. Chen, 1986, Biochimica et biophysica acta.

Aminopyridine-based c-Jun N-terminal kinase inhibitors with cellular activity and minimal cross-kinase activity.

Chaohong Sun, E. Olejniczak, Eric F. Johnson, 2006, Journal of medicinal chemistry.

Discovery of potent, highly selective, and orally bioavailable pyridine carboxamide c-Jun NH2-terminal kinase inhibitors.

Eric F. Johnson, C. Abad-Zapatero, H. Sham, 2006, Journal of Medicinal Chemistry.

The CD4 receptor is complexed in detergent lysates to a protein-tyrosine kinase (pp58) from human T lymphocytes.

C. Rudd, J. Trevillyan, S. Schlossman, 1988, Proceedings of the National Academy of Sciences of the United States of America.

Protein tyrosine phosphatase 1B as a target for the treatment of impaired glucose tolerance and type II diabetes.

J. Trevillyan, Gang Liu, 2002, Current opinion in investigational drugs.

p56lck interactions accelerate autophosphorylation and enhance activity toward exogenous substrates.

J. Trevillyan, R. Lehr, C. Faltynek, 1994, Archives of biochemistry and biophysics.

Aminopyridine carboxamides as c-Jun N-terminal kinase inhibitors: targeting the gatekeeper residue and beyond.

H. Sham, R. Gum, D. Haasch, 2006, Bioorganic & medicinal chemistry letters.

Differential inhibition of T cell receptor signal transduction and early activation events by a selective inhibitor of protein-tyrosine kinase.

J. Trevillyan, C. Phillips, Y. Lu, 1990, Journal of immunology.

c-Jun N-terminal kinase pathways in diabetes.

Ruojing Yang, J. Trevillyan, 2008, The international journal of biochemistry & cell biology.

Potent Inhibition of NFAT Activation and T Cell Cytokine Production by Novel Low Molecular Weight Pyrazole Compounds*

Julie A. Wilkins, U. Warrior, Yung-wu Chen, 2001, The Journal of Biological Chemistry.

Pyrrolidine-constrained phenethylamines: The design of potent, selective, and pharmacologically efficacious dipeptidyl peptidase IV (DPP4) inhibitors from a lead-like screening hit.

G. L. Hamilton, K. Longenecker, H. Sham, 2007, Bioorganic & medicinal chemistry letters.

“The next big thing” in diabetes: clinical progress on DPP‐IV inhibitors

J. Trevillyan, T. V. von Geldern, 2006 .

Reduction of protein-tyrosine phosphatase-1B increases insulin signaling in FAO hepatoma cells.

C. Rondinone, J. Trevillyan, Harriet T. Smith, 2003, Biochemical and biophysical research communications.

Hemodynamic effects of potent and selective JNK inhibitors in anesthetized rats: implication for targeting protein kinases in metabolic diseases.

H. Sham, D. Beno, J. Trevillyan, 2007, Bioorganic & medicinal chemistry letters.

Protein tyrosine phosphatase 1B reduction regulates adiposity and expression of genes involved in lipogenesis.

J. Waring, R. Ulrich, B. Monia, 2002, Diabetes.

Protein Tyrosine Phosphatase 1B Reduction Regulates Adiposity and Expression of Genes Involved in

J. Waring, R. Ulrich, B. Monia, 2002 .

3,5-Bis(trifluoromethyl)pyrazoles: a novel class of NFAT transcription factor regulator.

Xiaoping Zhou, U. Warrior, C. Wegner, 2000, Journal of medicinal chemistry.

A Dominant-negative p38 MAPK Mutant and Novel Selective Inhibitors of p38 MAPK Reduce Insulin-stimulated Glucose Uptake in 3T3-L1 Adipocytes without Affecting GLUT4 Translocation*

R. Somwar, A. Klip, C. Rondinone, 2002, The Journal of Biological Chemistry.

Effect of bradykinin metabolism inhibitors on evoked hypotension in rats: rank efficacy of enzymes associated with bradykinin‐mediated angioedema

J. Segreti, R. Fryer, J. Trevillyan, 2008, British journal of pharmacology.

Inhibition of p56lckTyrosine Kinase by Isothiazolones

U. Warrior, Yung-wu Chen, P. Wiedeman, 1999 .

Phosphatidylinositol 3‐kinase activity is not essential for CD28 costimulatory activity in Jurkat T cells: studies with a selective inhibitor, wortmannin

Yiling Lu, J. Trevillyan, C. Phillips, 1995, European journal of immunology.

The CD4 receptor is complexed in detergent lysates to a protein-tyrosine kinase (pp58) from human T lymphocytes.

C. Rudd, J. Trevillyan, S. Schlossman, 1988, Proceedings of the National Academy of Sciences of the United States of America.

Dipeptidyl peptidase IV inhibitors for the treatment of impaired glucose tolerance and type 2 diabetes.

P. Wiedeman, J. Trevillyan, 2003, Current opinion in investigational drugs.

A macrolactam inhibitor of T helper type 1 and T helper type 2 cytokine biosynthesis for topical treatment of inflammatory skin diseases.

J. Trevillyan, G. Carter, K. Marsh, 1999, The Journal of investigative dermatology.

Antifungal rapamycin analogues with reduced immunosuppressive activity.

H. Ding, J. Trevillyan, A. Sarthy, 2000, Bioorganic & medicinal chemistry letters.

CD28-induced T cell activation. Evidence for a protein-tyrosine kinase signal transduction pathway.

J. Trevillyan, C. Phillips, Y. Lu, 1992, Journal of immunology.

Discovery of 2-[4-{{2-(2S,5R)-2-cyano-5-ethynyl-1-pyrrolidinyl]-2-oxoethyl]amino]- 4-methyl-1-piperidinyl]-4-pyridinecarboxylic acid (ABT-279): a very potent, selective, effective, and well-tolerated inhibitor of dipeptidyl peptidase-IV, useful for the treatment of diabetes.

K. Longenecker, J. Segreti, H. Sham, 2006, Journal of medicinal chemistry.

The CD4 and CD8 antigens are coupled to a protein-tyrosine kinase (p56lck) that phosphorylates the CD3 complex.

C. Rudd, J. Trevillyan, S. Schlossman, 1989, Proceedings of the National Academy of Sciences of the United States of America.

TH1 and TH2 cytokine inhibition by 3,5-bis(trifluoromethyl)pyrazoles, a novel class of immunomodulators.

Julie A. Wilkins, U. Warrior, M. Nakane, 2002, Cellular immunology.

High tyrosine-specific protein kinase activity in normal human peripheral blood lymphocytes.

J. Trevillyan, T. Linna, A. Nordstrom, 1985, Biochimica et biophysica acta.

A High-Capacity Scintillation Proximity Assay for the Discovery and Evaluation of ZAP-70 Tandem SH2 Domain Antagonists

U. Warrior, H. Yoon, J. Trevillyan, 1998 .

CD28‐dependent killing by human YT cells requires phosphatidylinositol 3‐kinase activation

Yiling Lu, J. Trevillyan, C. Phillips, 1996, European journal of immunology.

Tumor-promoting phorbol esters stimulate the phosphorylation of ribosomal protein S6 in quiescent Reuber H35 hepatoma cells.

C. Byus, J. Trevillyan, R. Kulkarni, 1984, The Journal of biological chemistry.

In Vitro Enzymatic Assays of Protein Tyrosine Phosphatase 1B

J. Trevillyan, T. Lubben, M. Stashko, 2001, Current protocols in pharmacology.

Discovery and structure-activity relationships of piperidinone- and piperidine-constrained phenethylamines as novel, potent, and selective dipeptidyl peptidase IV inhibitors.

K. Longenecker, H. Sham, Xiaofen Li, 2007, Journal of medicinal chemistry.

Synthesis and SAR of 1,9-dihydro-9-hydroxypyrazolo[3,4-b]quinolin-4-ones as novel, selective c-Jun N-terminal kinase inhibitors.

C. Abad-Zapatero, H. Sham, R. Gum, 2006, Bioorganic & medicinal chemistry letters.

PTP1B antisense oligonucleotide lowers PTP1B protein, normalizes blood glucose, and improves insulin sensitivity in diabetic mice

J. Waring, R. Ulrich, S. Crosby, 2002, Proceedings of the National Academy of Sciences of the United States of America.

Activation of cyclic adenosine 3':5'-monophosphate-dependent protein kinase in H35 hepatoma and Chinese hamster ovary cells by a phorbol ester tumor promoter.

C. Byus, J. Trevillyan, W. Fletcher, 1983, Cancer research.

Control of cyclic adenosine 3',5'-monophosphate levels by depolarizing agents in fungi

J. Trevillyan, M. Pall, 1979, Journal of bacteriology.

Discovery of ascomycin analogs with potent topical but weak systemic activity for treatment of inflammatory skin diseases.

P. Wiedeman, J. Trevillyan, K. Marsh, 1998, Current pharmaceutical design.

Deficient cyclic adenosine 3',5'-monophosphate control in mutants of two genes of Neurospora crassa

N. Hinman, J. Trevillyan, M. Pall, 1981, Molecular and cellular biology.

Identification of the human T-lymphocyte protein-tyrosine kinase by peptide-specific antibodies.

D. Maley, J. Trevillyan, C. Phillips, 1986, Biochemical and biophysical research communications.

Association of the p56lck protein tyrosine kinase with the FCγRIIIA/CD16 complex in human natural killer cells

Yiling Lu, J. Trevillyan, C. Phillips, 1993 .

Selective protein tyrosine phosphatase 1B inhibitors: targeting the second phosphotyrosine binding site with non-carboxylic acid-containing ligands.

Gang Liu, Cristina M Rondinone, P. Hajduk, 2003, Journal of medicinal chemistry.

Identification and partial characterization of an ectoATPase expressed by human natural killer cells.

J. Trevillyan, Y. Lu, C. Phillips, 1993, Biochemistry.

Potent, selective inhibitors of protein tyrosine phosphatase 1B.

Gang Liu, P. Hajduk, C. Abad-Zapatero, 2003, Bioorganic & medicinal chemistry letters.

Discovery of ((4R,5S)-5-amino-4-(2,4,5- trifluorophenyl)cyclohex-1-enyl)-(3- (trifluoromethyl)-5,6-dihydro- [1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)methanone (ABT-341), a highly potent, selective, orally efficacious, and safe dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.

K. Longenecker, H. Sham, R. Fryer, 2006, Journal of medicinal chemistry.

CD28 signal transduction: tyrosine phosphorylation and receptor association of phosphoinositide‐3 kinase correlate with Ca2+‐independent costimulatory activity

Yiling Lu, J. Trevillyan, J. Bjorndahl, 1994, European journal of immunology.

Antisense protein tyrosine phosphatase 1B reverses activation of p38 mitogen-activated protein kinase in liver of ob/ob mice.

J. Waring, R. Ulrich, C. Rondinone, 2003, Molecular endocrinology.

Development of a p38 Kinase Binding Assay for High Throughput Screening

R. Simmer, U. Warrior, D. Burns, 1999, Journal of biomolecular screening.

Discovery and structure-activity relationship of oxalylarylaminobenzoic acids as inhibitors of protein tyrosine phosphatase 1B.

Gang Liu, P. Hajduk, S. Fesik, 2003, Journal of medicinal chemistry.

PTP1B antisense-treated mice show regulation of genes involved in lipogenesis in liver and fat

J. Waring, R. Ulrich, C. Rondinone, 2003, Molecular and Cellular Endocrinology.

Crystal structures of DPP-IV (CD26) from rat kidney exhibit flexible accommodation of peptidase-selective inhibitors.

Vincent S Stoll, K. Longenecker, V. Stoll, 2006, Biochemistry.

T cell activation induces a noncoding RNA transcript sensitive to inhibition by immunosuppressant drugs and encoded by the proto-oncogene, BIC.

D. Halbert, D. Haasch, Yung-wu Chen, 2002, Cellular immunology.

Protein tyrosine phosphatase 1B negatively regulates leptin signaling in a hypothalamic cell line

D. White, D. Haasch, P. Kroeger, 2002, Molecular and Cellular Endocrinology.

Fragment screening and assembly: a highly efficient approach to a selective and cell active protein tyrosine phosphatase 1B inhibitor.

Gang Liu, Hongyu Zhao, Cristina M Rondinone, 2003, Journal of medicinal chemistry.

Discovery of a new class of 4-anilinopyrimidines as potent c-Jun N-terminal kinase inhibitors: Synthesis and SAR studies.

C. Abad-Zapatero, H. Sham, C. Rondinone, 2007, Bioorganic & medicinal chemistry letters.

Liver-specific Knockdown of JNK1 Up-regulates Proliferator-activated Receptor γ Coactivator 1β and Increases Plasma Triglyceride despite Reduced Glucose and Insulin Levels in Diet-induced Obese Mice*

E. Bush, P. Jung, C. Rondinone, 2007, Journal of Biological Chemistry.

Insulin- and phorbol ester-stimulated phosphorylation of ribosomal protein S6.

C. Byus, O. Perisic, J. Trevillyan, 1985, The Journal of biological chemistry.

Reduction of protein tyrosine phosphatase 1B increases insulin-dependent signaling in ob/ob mice.

R. Ulrich, C. Rondinone, R. Gum, 2003, Diabetes.

Zotarolimus, a Novel Sirolimus Analogue With Potent Anti-proliferative Activity on Coronary Smooth Muscle Cells and Reduced Potential for Systemic Immunosuppression

Yung-wu Chen, J. Trevillyan, G. Carter, 2007, Journal of cardiovascular pharmacology.

Isolation and properties of a cyclic AMP-binding protein from Neurospora. Evidence for its role as the regulatory subunit of cyclic AMP-dependent protein kinase.

J. Trevillyan, M. Pall, 1982, The Journal of biological chemistry.

Cyclic AMP and tumor promoters cause differential induction of ornithine decarboxylase and accumulation of putrescine in Chinese hamster ovary cells deficient in cyclic AMP-dependent protein kinase.

C. Byus, J. Trevillyan, 1983, Biochimica et biophysica acta.

Inhibition of p56(lck) tyrosine kinase by isothiazolones.

U. Warrior, P. Wiedeman, J. Trevillyan, 1999, Archives of biochemistry and biophysics.

Expression, purification, and enzymatic characterization of the dual specificity mitogen-activated protein kinase phosphatase, MKP-4.

T. Parsons, S. Hong, J. Trevillyan, 2005, Bioorganic chemistry.

Isoxazole carboxylic acids as protein tyrosine phosphatase 1B (PTP1B) inhibitors.

P. Hajduk, C. Abad-Zapatero, C. Rondinone, 2004, Bioorganic & medicinal chemistry letters.

Identification of a monoacid-based, cell permeable, selective inhibitor of protein tyrosine phosphatase 1B.

P. Hajduk, C. Abad-Zapatero, Xiaofen Li, 2003, Bioorganic & Medicinal Chemistry Letters.

Discovery and SAR of novel, potent and selective protein tyrosine phosphatase 1B inhibitors.

Gang Liu, C. Abad-Zapatero, Xiaofen Li, 2003, Bioorganic & medicinal chemistry letters.

Discovery, structure-activity relationship, and pharmacological evaluation of (5-substituted-pyrrolidinyl-2-carbonyl)-2-cyanopyrrolidines as potent dipeptidyl peptidase IV inhibitors.

H. Sham, Xiaofen Li, D. Beno, 2006, Journal of Medicinal Chemistry.

Rapamycin analogs with reduced systemic exposure.

P. Wiedeman, J. Trevillyan, G. Carter, 2005, Bioorganic & medicinal chemistry letters.

Reduction of PTP1B induces differential expression of PI3-kinase (p85α) isoforms

C. Rondinone, R. Gum, J. Trevillyan, 2004 .

Putting Thought to Paper: A μARCS Protease Screen

U. Warrior, D. Burns, D. Groebe, 2003 .

Discovery and structure-activity relationship of oxalylarylaminobenzoic acids as inhibitors of protein tyrosine phosphatase 1B.

P. Hajduk, S. Fesik, C. Abad-Zapatero, 2003, Journal of medicinal chemistry.

Treatment of zucker diabetic fatty rats with antisense oligonucleotide to phosphotyrosine phosphatase-1B for 5 weeks halts development of diabetes

E. Bush, J. Trevillyan, P. Jacobson, 2001 .